<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="185363">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00680823</url>
  </required_header>
  <id_info>
    <org_study_id>PRO08030283</org_study_id>
    <nct_id>NCT00680823</nct_id>
  </id_info>
  <brief_title>Study of Intramuscular Ropivacaine Injections for Treatment of Pediatric Headache</brief_title>
  <official_title>Is Paraspinal Intramuscular Ropivacaine Injection an Effective Treatment for Headache in a Pediatric Emergency Department?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Children's Hospital of Pittsburgh</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objective: To determine if lower paracervical intramuscular ropivacaine injection is an
      effective treatment for pediatric headache in an emergency department setting.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Methods: The study will be a double-blind randomized control trial. Patients will be
      randomly assigned to receive either intramuscular injection of the lower cervical
      paraspinous muscles with 1 mL of 0.5% ropivacaine on each side, placebo injections with 1 mL
      normal saline on each side, or no intervention at all. If randomized to an injection, the
      investigator and the patient will both be blinded as to the nature of the injection.

      The location of the child's pain as well as severity will be assessed immediately prior to
      intervention and every 10 minutes for 30 minutes. If after 30 minutes relief is insufficient
      for discharge to home, intravenous treatment will be instituted according to current
      protocol. Pain will be reassessed at the time of ultimate disposition. The scale used to
      assess severity will vary based on the child's age.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary outcome will be pain relief sufficient for discharge from the emergency department.</measure>
    <time_frame>3 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>complete resolution of headache</measure>
    <time_frame>3 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>admission</measure>
    <time_frame>3 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time from presentation to ultimate disposition</measure>
    <time_frame>3 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>re-presentation to the emergency department with headache within 72 hours of participating in the study</measure>
    <time_frame>72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>a change of greater than 1.5 on the numerical rating scale</measure>
    <time_frame>3 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Headache</condition>
  <condition>Migraine</condition>
  <arm_group>
    <arm_group_label>Ropivacaine Injections</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intramuscular injection of the lower cervical paraspinous muscles with 1.5 mL of 0.5% ropivacaine on each side.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal Saline Injections</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intramuscular injection of the lower cervical paraspinous muscles with 1.5 mL of normal saline on each side.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Observation</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Observation for 30 minutes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivacaine</intervention_name>
    <description>1.5 mL IM to each side in to the lower cervical paraspinous muscles x 1.</description>
    <arm_group_label>Ropivacaine Injections</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <description>1.5 mL IM to each side in to the lower cervical paraspinous muscles x 1.</description>
    <arm_group_label>Normal Saline Injections</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chief complaint of headache

          -  Age 7-17 years

        Exclusion Criteria:

          -  Presence of fever

          -  meningismus

          -  headache that wakes the child at night

          -  known organic brain disease, mass, or tumor

          -  history of stroke

          -  history of allergy to ropivacaine or other aminoacyl local anesthetics

          -  history of liver disease

          -  history of impaired cardiac function

          -  abnormal neurologic signs

          -  a focal neurologic abnormality on exam that is not a known component of the child's
             headache syndrome

          -  cognitive inability to communicate the intensity of pain.

          -  history of shunt or other intracranial hardware
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susan Sieminski, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital of Pittsburgh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <lastchanged_date>June 25, 2016</lastchanged_date>
  <firstreceived_date>May 16, 2008</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Children's Hospital of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Susan Sieminski, MD</investigator_full_name>
    <investigator_title>Pediatric Emergency Medicine Fellow</investigator_title>
  </responsible_party>
  <keyword>Headache</keyword>
  <keyword>Migraine</keyword>
  <keyword>Ropivacaine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Headache</mesh_term>
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ropivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
